Research programme: RNA therapeutics - TFF Phartmaceuticals
Latest Information Update: 28 Apr 2024
At a glance
- Originator TFF Pharmaceuticals
- Class RNA
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Respiration disorders
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for research development in Respiration-disorders in USA (Intranasal, Inhalant)
- 02 Apr 2020 Research programme: nucleic acid therapeutics - TFF Phartmaceuticals is available for licensing as of 26 Mar 2020. http://www.tffpharma.com.
- 26 Mar 2020 Early research in Respiration disorders in USA (unspecified route)